Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prospective Analysis and Comparison of Stress Echo to Real-Time Myocardial Contrast Stress Echo

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00575549
Expanded Access Status : No longer available
First Posted : December 18, 2007
Last Update Posted : December 10, 2018
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Thomas R. Porter, MD, University of Nebraska

Tracking Information
First Submitted Date December 14, 2007
First Posted Date December 18, 2007
Last Update Posted Date December 10, 2018
 
Descriptive Information
Brief Title Prospective Analysis and Comparison of Stress Echo to Real-Time Myocardial Contrast Stress Echo
Brief Summary The purpose of this study is to prospectively analyze and compare conventional stress echocardiograms and real-time myocardial contrast stress echocardiograms; and to determine the effect of contrast agents used during real-time myocardial contrast stress echocardiograms on serum troponin I levels.
Detailed Description To compare two different stress echocardiograms (conventional Stress echocardiograms or Real-time Myocardial Contrast Stress Echocardiograms) that are in routine clinical use. The information, including the digital images that are collected during the stress tests is used to determine if the usse of specialized imaging techniques and ultrasound contrast can better detect blockage in blood flow to the heart and predict how patients outcome may be affected by this detection of a blockage.
Study Type Expanded Access
Intervention Other: Dobutamine: Perflutren Lipid Microsphere
Dobutamine with starting dose of 10 micrograms/kg/min and increased gradually to a maximum dose of 50 micrograms/kg/min Definity will be infused continuously at a rate of 4mL/min
Other Name: Definity
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Expanded Access Status No longer available
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT00575549
Responsible Party Thomas R. Porter, MD, University of Nebraska
Study Sponsor University of Nebraska
Collaborators Bristol-Myers Squibb
Investigators
Principal Investigator: Thomas R Porter, MD UNMC
PRS Account University of Nebraska
Verification Date December 2018